#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

Jul 6, 20261h 44mSummary

In this episode of The Peter Attia Drive, Dr. Peter Attia presents a comprehensive overview of building strength and muscle mass, emphasizing their critical roles in longevity and healthspan. Originally aired as a subscriber-only AMA, this rebroadcast serves as a streamlined resource for listeners looking to understand the science behind physical training and its long-term benefits. The discussion highlights the vital distinction between muscle mass and muscle strength, noting that while both are important, strength is a more potent predictor of mortality. Attia explains why muscle acts as both a metabolic "sink" for glucose and an endocrine organ, providing protective effects against metabolic diseases and chronic inflammation. He also explores the concept of muscle as a protein reservoir, which is crucial for surviving periods of acute illness or surgery. Beyond the theory, the episode covers practical application, including the importance of grip strength as a health marker, the necessity of progressive overload, and the value of explosive power training for aging populations. Attia also addresses nutritional requirements, such as adequate protein intake, and discusses the importance of consistency and recovery in long-term exercise programming.

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

Jun 29, 20269 minSummary

In this episode of The Drive, Peter Attia dives into the complex relationship between GLP-1 receptor agonists—such as Ozempic, Wegovy, and Zepbound—and body composition. The discussion centers on the growing concern regarding the loss of lean mass during rapid weight loss, a phenomenon that has garnered significant attention as these medications become more prevalent. Attia explores the accuracy of using DEXA scans to measure lean mass and emphasizes that the clinical definition of lean mass can often be misleading, particularly when evaluating physical function and strength. The conversation moves beyond simple weight loss statistics to address how these drugs influence bone density, fracture risk, and different fat depots across the body. Attia addresses common fears surrounding muscle atrophy while highlighting the importance of proper patient counseling regarding nutrition and resistance training. By differentiating between clinical trial averages and real-world outcomes, he illustrates how modifiable behaviors can significantly mitigate risks. The episode also provides a forward-looking perspective on emerging drugs like retatrutide, framing the conversation around how patients can safely maintain muscle and bone health while undergoing medical weight management.

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.

Jun 22, 20261h 58mSummary

In this episode, Dr. Renato Tomioka, a leading expert in reproductive medicine and gynecologic surgery, provides an in-depth exploration of endometriosis and adenomyosis, two prevalent yet frequently overlooked conditions. He clarifies the distinct pathologies of these diseases: endometriosis involves endometrial-like tissue outside the uterus, while adenomyosis occurs when this tissue invades the muscular wall of the uterus. Dr. Tomioka emphasizes that both conditions are often misunderstood and misdiagnosed, leading to a typical diagnostic delay of five to twelve years. He explains that modern shifts in reproductive patterns—such as the increased number of ovulatory cycles in a woman's lifetime compared to previous centuries—may be contributing to their rising prevalence. The conversation covers the diagnostic transition from invasive surgical laparoscopy toward specialized ultrasound and MRI, highlighting the importance of early intervention to prevent central pain sensitization. The discussion further extends to the intersections between these conditions, infertility, and reproductive aging. Dr. Tomioka outlines the nuances of treatment, including the complex decision-making process between hormonal therapies and surgery, while providing crucial insights into how female age and chromosomal quality impact long-term fertility outcomes.

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy

Jun 15, 202650 minSummary

In this episode of The Drive, the host explores the complexities of breast cancer screening, addressing why many women remain confused about guidelines and why mortality rates persist despite the availability of effective tools. The discussion centers on moving beyond generic population-level recommendations to create a personalized screening strategy that maximizes an individual's chances of early detection. The episode emphasizes that while mammography is the foundation of screening, it is not a one-size-fits-all solution. Key insights include the critical importance of performing formal risk assessments by age 25, understanding the impact of breast density, and recognizing that risk factors—including genetics, family history, and ancestry—must be evaluated holistically. The host explains the hierarchy of imaging, noting that for high-risk individuals, mammography alone is often insufficient and should be supplemented with more sensitive tools like breast MRI or contrast-enhanced mammography. Ultimately, the host argues that screening should be a deliberate, personalized process. By weighing the benefit of early detection against the potential for false positives and diagnostic anxiety, women can make informed decisions to optimize their screening protocols, ensuring the best possible outcome for their specific health profile.

#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.

Jun 8, 20261h 40mSummary

In this episode of The Drive, host Peter Attia welcomes back renowned lipidologist Dr. Tom Dayspring for a technical, deep-dive discussion on the complex relationship between lipidology and brain health. The conversation begins by establishing a baseline understanding of cholesterol transport in the periphery, clearly distinguishing how the body utilizes ApoB-containing lipoproteins and HDL to manage cholesterol. A primary focus of the episode is the brain's unique cholesterol system, which operates almost entirely independently of the rest of the body. Dr. Dayspring explains why the blood-brain barrier prevents peripheral lipoproteins from entering the brain, emphasizing that the brain synthesizes its own cholesterol to support the massive requirements of myelin and cellular integrity. The discussion further explores the role of the APOE genotype in Alzheimer’s disease risk, specifically examining the potential links between cholesterol homeostasis, amyloid plaques, and tau proteins. Finally, the pair addresses the nuances of lipid-lowering therapies—including statins and omega-3 fatty acids—and clarifies common misconceptions regarding the risks and benefits of lowering LDL cholesterol for neurodegenerative disease prevention. It is a vital, evidence-based conversation for those seeking to understand the intricate interplay between cardiovascular health and long-term brain function.

#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they're working for you

May 25, 202613 minSummary

In this episode of The Peter Attia Drive, Peter Attia addresses the common pitfalls individuals encounter when navigating the complex world of medications and supplements. He argues that most people approach these interventions incorrectly by focusing on the "what" rather than the "why." Attia emphasizes that before considering any intervention, one must clearly define the problem using specific, actionable metrics, clear thresholds, and defined time horizons. Without this framework, he warns, it is easy to fall into the trap of subjective storytelling and placebo effects. The discussion further categorizes interventions into four distinct "jobs": disease treatment, symptom relief, risk reduction, and optimization. Attia explains that the evidence threshold and risk tolerance should shift significantly depending on which category a supplement or medication falls into. He cautions listeners to be particularly skeptical of "optimization" interventions, which often lack rigorous evidence and rely on vague mechanistic claims. By stressing the importance of evaluating the counterfactual—what would happen if no action were taken—Attia provides a practical, evidence-based approach to help listeners make more informed, objective decisions about their health.

#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results

May 18, 20261h 2mSummary

In this episode of The Peter Attia Drive, the host explores the complex and often misunderstood world of genetic testing. Peter Attia builds a practical framework for listeners to evaluate whether genetic testing is truly useful, emphasizing that many tests are probabilistic rather than deterministic. He cautions that while some results can be life-changing, others provide little actionable data, often serving as a poor substitute for direct phenotypic assessment through blood work, imaging, and clinical history. The discussion navigates the four major disease categories—cardiovascular, metabolic, cancer, and neurodegenerative conditions—to highlight where genetics offer genuine clinical value versus where they are oversold. Attia distinguishes between common, lower-impact genetic variants and high-penetrance mutations, such as those related to hereditary cancer syndromes or rare monogenic disorders. A significant portion of the episode is dedicated to the psychological impact of these results and the necessity of asking specific questions before testing, such as whether a result will meaningfully change a patient's behavior or clinical care. Ultimately, the episode encourages listeners to prioritize clarity over curiosity and to ensure that genetic testing is used as a precise tool rather than a speculative crystal ball for future health.

#389 - Thinking scientifically: why it's hard, why it matters, and a practical toolkit

Apr 27, 202653 minSummary

In this episode of The Peter Attia Drive, Peter examines the foundational principles of scientific thinking and why it remains an essential yet challenging skill in the modern era. He explores the cognitive biases and evolutionary instincts that often hinder objective reasoning, making it difficult to distinguish evidence from personal belief in an age of rampant misinformation. Listeners will learn how to navigate uncertainty, differentiate between scientific knowledge and mathematical proof, and understand why updating one’s views in light of new evidence is a sign of intellectual strength. The episode provides a comprehensive, practical toolkit for improving decision-making, including techniques to identify bias, evaluate expert credibility, and challenge personal assumptions. By the end of the discussion, listeners gain a structured framework designed to foster more disciplined, effective, and evidence-based thinking in their daily lives.

#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

Apr 20, 202646 minSummary

In this episode of The Peter Attia Drive, Peter Attia conducts a thorough examination of prostate cancer screening, addressing the concerning rise in advanced and metastatic diagnoses. He argues that current clinical guidelines are failing men and explores how modern diagnostic tools can reverse these trends. Listeners will learn why a single PSA value is insufficient and why tracking PSA velocity and density over time, combined with MRI imaging, offers a more accurate approach to detection. The discussion also covers the critical role of active surveillance in preventing overtreatment, the limitations of historical clinical trials used to discourage screening, and the importance of accounting for medications like finasteride that can mask warning signs. Ultimately, Attia presents a compelling, data-driven case for proactive, refined screening strategies as a necessary path toward eliminating prostate cancer mortality.

#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

Apr 13, 202622 minSummary

In this episode, Peter Attia addresses the complex and often confusing world of peptides. As these compounds gain popularity for applications ranging from muscle repair to longevity, Peter emphasizes the need for a rigorous, repeatable framework to evaluate them. Rather than dismissing or endorsing peptides, he provides a detailed methodology for assessing their mechanisms, safety profiles, and clinical evidence. He distinguishes between FDA-approved therapeutics and the loosely regulated products found in the biohacking gray market. Through specific case studies—including SS-31, Melanotan-II, CJC-1295, and BPC 157—Peter illustrates how to analyze the actual science versus the hype. Listeners will gain a deeper understanding of the risks associated with gray-market manufacturing, the limitations of current data, and the regulatory challenges that define this rapidly growing field. This episode is essential for anyone seeking a sober, scientific perspective on peptide-based wellness trends.